Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates
The University of Texas MD Anderson Cancer Center · Novartis (Switzerland)
Abstract
Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates. The incidence and risk factors associated with this disorder have not been clearly defined.
We conducted a retrospective analysis of 4019 patients treated with intravenous bisphosphonates between 1996 and 2004. Our goals were to estimate the frequency, understand the clinical presentation, and identify risk factors associated with ONJ development.
Citation impact
- FWCI
- 31.06
- Percentile
- 100%
- References
- 38
Authors
14- AOAna O. HoffCorresponding
The University of Texas MD Anderson Cancer Center
- BBBéla B. Toth
The University of Texas MD Anderson Cancer Center
- KAKadri Altundağ
The University of Texas MD Anderson Cancer Center
- MMMarcella M. Johnson
The University of Texas MD Anderson Cancer Center
- CLCarla L. Warneke
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Osteonecrosis of the jaw
- Medicine
- Cancer
- Dentistry
- Internal medicine
- Bisphosphonate
- Osteoporosis